Key result
Polyclonal digoxin immunoassays showed significant positive or bidirectional interference from digitoxin, whereas a monoclonal chemiluminescent assay showed no significant interference.
Case Report (n=1)
Digoxin immunoassays using polyclonal antibodies can exhibit significant bidirectional interference from digitoxin, highlighting the need for highly specific monoclonal assays with cross-reactivity <0.1%.
Answers are grounded in this paper and cite their sources.
May warrant preferring monoclonal digoxin assays clinically; leaves open broader validation across populations.
The importance of high specificity in immunoassays used in therapeutic monitoring is highlighted by a case study in which therapeutic-to-toxic borderline digoxin levels were measured by a digoxin immunoassay in the serum sample from a patient administered digitoxin rather than digoxin. The sample, mistakenly sent to the laboratory for digoxin analysis, gave discordant results in three digoxin immunoassays: 1.99 and 0.79 ng/ml in assays using polyclonal antibodies (fluorescence-polarization immunoassay and microparticle enzyme immunoassay, respectively), and <0.1 ng/ml in a chemiluminescent immunoassay using more specific monoclonal antibody. The presence of digitoxin (approximately 40 ng/ml) in the sample was confirmed by three different digitoxin immunoassays. Based on these results, the interference of different levels of digitoxin was studied in the presence of 0, 0.85, 1.9, and 4.7 ng/ml digoxin in all three digoxin assays. The chemiluminescent assay showed no significant interference. The fluorescence-polarization immunoassay showed positive interference in all cases; however, the microparticle enzyme immunoassay showed a bidirectional interference: a positive interference observed at digoxin level <1.8 ng/ml, changing to a negative interference at higher digoxin concentrations. The authors conclude that in countries such as Germany, where both digoxin and digitoxin may be prescribed, caution should be used to interpret digoxin immunoassay results. Digoxin assays, with cross-reactivity to digitoxin <0.1% should be used.
No takes yet. Share an insight, caveat, or question.
Datta et al. (1998) conducted a case report in Therapeutic drug monitoring of digoxin/digitoxin (n=1). Digoxin immunoassays vs. Different immunoassay methods (polyclonal vs monoclonal) was evaluated on Digoxin level measurement and digitoxin interference. Polyclonal digoxin immunoassays showed significant positive or bidirectional interference from digitoxin, whereas a monoclonal chemiluminescent assay showed no significant interference.
Synapse has enriched 10 related papers. Consider them for comparative context: